Adaptive Total Current Assets vs Total Assets Analysis

ADPT Stock  USD 2.75  0.15  5.77%   
Adaptive Biotechnologies financial indicator trend analysis is way more than just evaluating Adaptive Biotechnologies prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Adaptive Biotechnologies is a good investment. Please check the relationship between Adaptive Biotechnologies Total Current Assets and its Total Assets accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Adaptive Biotechnologies Corp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey.

Total Current Assets vs Total Assets

Total Current Assets vs Total Assets Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Adaptive Biotechnologies Total Current Assets account and Total Assets. At this time, the significance of the direction appears to have almost identical trend.
The correlation between Adaptive Biotechnologies' Total Current Assets and Total Assets is 0.97. Overlapping area represents the amount of variation of Total Current Assets that can explain the historical movement of Total Assets in the same time period over historical financial statements of Adaptive Biotechnologies Corp, assuming nothing else is changed. The correlation between historical values of Adaptive Biotechnologies' Total Current Assets and Total Assets is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Current Assets of Adaptive Biotechnologies Corp are associated (or correlated) with its Total Assets. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Assets has no effect on the direction of Total Current Assets i.e., Adaptive Biotechnologies' Total Current Assets and Total Assets go up and down completely randomly.

Correlation Coefficient

0.97
Relationship DirectionPositive 
Relationship StrengthVery Strong

Total Current Assets

The total value of all assets that are expected to be converted into cash within one year or during the normal operating cycle.

Total Assets

Total assets refers to the total amount of Adaptive Biotechnologies assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Adaptive Biotechnologies books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.
Most indicators from Adaptive Biotechnologies' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Adaptive Biotechnologies current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Adaptive Biotechnologies Corp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey.
Selling General Administrative is likely to drop to about 57.1 M in 2024. Sales General And Administrative To Revenue is likely to drop to 0.35 in 2024
 2021 2022 2023 2024 (projected)
Gross Profit105.0M127.4M72.5M78.9M
Total Revenue154.3M185.3M170.3M123.7M

Adaptive Biotechnologies fundamental ratios Correlations

0.890.950.990.870.970.890.980.52-0.640.610.690.90.620.49-0.370.950.56-0.270.920.440.930.92-0.950.890.86
0.890.980.910.830.920.990.930.69-0.840.80.510.850.520.2-0.470.80.8-0.360.950.750.790.92-0.930.960.96
0.950.980.970.880.970.980.980.64-0.80.760.60.910.570.36-0.450.860.75-0.340.970.640.840.96-0.980.970.96
0.990.910.970.90.990.90.990.54-0.670.660.660.910.610.51-0.380.940.61-0.270.950.450.910.94-0.970.930.88
0.870.830.880.90.930.790.860.66-0.740.850.30.670.450.64-0.470.880.77-0.360.940.360.90.93-0.920.920.76
0.970.920.970.990.930.910.980.61-0.720.720.590.890.550.5-0.420.910.67-0.310.980.50.90.96-0.980.960.9
0.890.990.980.90.790.910.940.65-0.820.750.590.90.550.18-0.430.760.77-0.320.940.760.730.9-0.930.950.97
0.980.930.980.990.860.980.940.56-0.710.660.690.950.610.44-0.390.880.64-0.280.950.530.850.94-0.980.930.93
0.520.690.640.540.660.610.650.56-0.950.770.050.45-0.210.11-0.930.460.77-0.880.70.670.490.78-0.690.720.68
-0.64-0.84-0.8-0.67-0.74-0.72-0.82-0.71-0.95-0.87-0.2-0.61-0.06-0.120.8-0.54-0.90.74-0.82-0.78-0.55-0.860.8-0.85-0.82
0.610.80.760.660.850.720.750.660.77-0.870.030.450.290.32-0.530.60.98-0.450.830.580.640.81-0.760.850.7
0.690.510.60.660.30.590.590.690.05-0.20.030.820.540.16-0.040.560.040.00.480.290.470.48-0.570.450.56
0.90.850.910.910.670.890.90.950.45-0.610.450.820.570.31-0.330.740.47-0.230.840.540.680.83-0.90.820.92
0.620.520.570.610.450.550.550.61-0.21-0.060.290.540.570.380.390.60.250.490.480.090.570.38-0.480.460.46
0.490.20.360.510.640.50.180.440.11-0.120.320.160.310.38-0.130.570.17-0.060.43-0.450.590.48-0.490.360.19
-0.37-0.47-0.45-0.38-0.47-0.42-0.43-0.39-0.930.8-0.53-0.04-0.330.39-0.13-0.33-0.520.99-0.49-0.46-0.35-0.640.53-0.49-0.49
0.950.80.860.940.880.910.760.880.46-0.540.60.560.740.60.57-0.330.5-0.230.850.290.990.85-0.860.810.7
0.560.80.750.610.770.670.770.640.77-0.90.980.040.470.250.17-0.520.5-0.450.80.70.530.77-0.730.840.73
-0.27-0.36-0.34-0.27-0.36-0.31-0.32-0.28-0.880.74-0.450.0-0.230.49-0.060.99-0.23-0.45-0.37-0.42-0.25-0.540.42-0.38-0.37
0.920.950.970.950.940.980.940.950.7-0.820.830.480.840.480.43-0.490.850.8-0.370.590.840.97-0.981.00.92
0.440.750.640.450.360.50.760.530.67-0.780.580.290.540.09-0.45-0.460.290.7-0.420.590.270.55-0.540.660.74
0.930.790.840.910.90.90.730.850.49-0.550.640.470.680.570.59-0.350.990.53-0.250.840.270.85-0.840.80.67
0.920.920.960.940.930.960.90.940.78-0.860.810.480.830.380.48-0.640.850.77-0.540.970.550.85-0.990.960.9
-0.95-0.93-0.98-0.97-0.92-0.98-0.93-0.98-0.690.8-0.76-0.57-0.9-0.48-0.490.53-0.86-0.730.42-0.98-0.54-0.84-0.99-0.97-0.93
0.890.960.970.930.920.960.950.930.72-0.850.850.450.820.460.36-0.490.810.84-0.381.00.660.80.96-0.970.93
0.860.960.960.880.760.90.970.930.68-0.820.70.560.920.460.19-0.490.70.73-0.370.920.740.670.9-0.930.93
Click cells to compare fundamentals

Adaptive Biotechnologies Account Relationship Matchups

Adaptive Biotechnologies fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets912.3M1.1B923.3M856.6M661.1M811.6M
Other Current Liab12.9M25.1M25.0M28.4M22.3M19.9M
Total Current Liabilities78.3M105.2M113.8M109.8M88.0M84.7M
Total Stockholder Equity571.0M743.3M604.0M464.2M308.4M347.0M
Other Liab226.3M163.6M98.8M184.0M211.6M125.4M
Net Tangible Assets440.1M614.1M476.5M338.4M389.1M205.2M
Property Plant And Equipment Net60.4M139.0M172.9M164.2M120.3M108.4M
Current Deferred Revenue61.0M73.3M80.5M64.1M48.6M55.7M
Net Debt(60.0M)(15.6M)(27.3M)18.0M164.4M172.6M
Retained Earnings(365.5M)(511.6M)(718.9M)(919.1M)(1.1B)(1.1B)
Accounts Payable4.5M3.2M3.3M8.1M7.7M4.8M
Cash96.6M123.4M139.1M90.0M65.1M102.9M
Non Current Assets Total299.6M389.5M520.6M294.5M250.9M324.4M
Non Currrent Assets Other2.9M2.7M3.0M4.5M(1.5M)(1.5M)
Other Assets39.5M2.7M3.0M4.5M4.0M6.7M
Cash And Short Term Investments576.9M688.3M353.1M498.2M346.4M443.1M
Net Receivables12.7M10.0M17.4M40.1M39.0M20.4M
Common Stock Shares Outstanding69.2M131.2M140.4M142.5M144.4M131.8M
Short Term Investments480.3M564.8M214.0M408.2M281.3M340.3M
Liabilities And Stockholders Equity912.3M1.1B923.3M856.6M661.1M811.6M
Non Current Liabilities Total263.0M268.0M205.4M282.7M264.8M276.3M
Capital Surpluse935.8M1.3B1.3B1.4B1.6B910.1M
Inventory9.1M14.1M19.3M14.5M14.4M13.2M
Other Current Assets14.1M14.5M13.0M9.4M10.4M10.6M
Other Stockholder Equity23.5M1.3B1.3B1.4B1.5B865.0M
Total Liab341.3M373.1M319.2M392.5M352.9M337.9M
Net Invested Capital571.0M743.3M604.0M464.2M308.4M347.0M
Property Plant And Equipment Gross60.4M139.0M172.9M164.2M193.6M119.9M
Total Current Assets612.7M726.9M402.7M562.1M410.2M487.2M
Accumulated Other Comprehensive Income671K893K(1.1M)(4.1M)215K225.8K
Net Working Capital534.4M621.7M288.9M452.4M322.2M402.6M
Intangible Assets11.9M10.2M8.5M6.8M5.1M8.2M

Pair Trading with Adaptive Biotechnologies

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Adaptive Biotechnologies position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Adaptive Biotechnologies will appreciate offsetting losses from the drop in the long position's value.

Moving together with Adaptive Stock

  0.81DRMA Dermata Therapeutics Financial Report 9th of May 2024 PairCorr
  0.82DVAX Dynavax Technologies Financial Report 7th of May 2024 PairCorr
  0.62VTRS Viatris Earnings Call This WeekPairCorr
  0.76EGRX Eagle PharmaceuticalsPairCorr

Moving against Adaptive Stock

  0.82ACB Aurora Cannabis Downward RallyPairCorr
  0.81CGC Canopy Growth Corp Downward RallyPairCorr
  0.73FLGC Flora Growth Corp Financial Report 20th of May 2024 PairCorr
  0.71HCM HUTCHMED DRCPairCorr
  0.6ELYM Eliem Therapeutics TrendingPairCorr
The ability to find closely correlated positions to Adaptive Biotechnologies could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Adaptive Biotechnologies when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Adaptive Biotechnologies - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Adaptive Biotechnologies Corp to buy it.
The correlation of Adaptive Biotechnologies is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Adaptive Biotechnologies moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Adaptive Biotechnologies moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Adaptive Biotechnologies can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Adaptive Biotechnologies is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Adaptive Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Adaptive Biotechnologies Corp Stock. Highlighted below are key reports to facilitate an investment decision about Adaptive Biotechnologies Corp Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Adaptive Biotechnologies Corp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey.
You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.

Complementary Tools for Adaptive Stock analysis

When running Adaptive Biotechnologies' price analysis, check to measure Adaptive Biotechnologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adaptive Biotechnologies is operating at the current time. Most of Adaptive Biotechnologies' value examination focuses on studying past and present price action to predict the probability of Adaptive Biotechnologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Adaptive Biotechnologies' price. Additionally, you may evaluate how the addition of Adaptive Biotechnologies to your portfolios can decrease your overall portfolio volatility.
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Is Adaptive Biotechnologies' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Adaptive Biotechnologies. If investors know Adaptive will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Adaptive Biotechnologies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.56)
Revenue Per Share
1.179
Quarterly Revenue Growth
(0.17)
Return On Assets
(0.17)
Return On Equity
(0.58)
The market value of Adaptive Biotechnologies is measured differently than its book value, which is the value of Adaptive that is recorded on the company's balance sheet. Investors also form their own opinion of Adaptive Biotechnologies' value that differs from its market value or its book value, called intrinsic value, which is Adaptive Biotechnologies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Adaptive Biotechnologies' market value can be influenced by many factors that don't directly affect Adaptive Biotechnologies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Adaptive Biotechnologies' value and its price as these two are different measures arrived at by different means. Investors typically determine if Adaptive Biotechnologies is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Adaptive Biotechnologies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.